AstraZeneca (LON:AZN) Price Target Raised to £180
by Amy Steele · The Cerbat GemAstraZeneca (LON:AZN – Get Free Report) had its target price upped by equities research analysts at Citigroup from £170 to £180 in a research note issued on Friday,London Stock Exchange reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price points to a potential upside of 16.94% from the company’s current price.
A number of other brokerages also recently issued reports on AZN. Deutsche Bank Aktiengesellschaft increased their price target on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Berenberg Bank increased their price target on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of £152.50.
AstraZeneca Price Performance
Shares of LON:AZN opened at £153.92 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 60.87. The firm has a market capitalization of £238.70 billion, a PE ratio of 23.54, a P/E/G ratio of 0.86 and a beta of 0.28. AstraZeneca has a twelve month low of GBX 9,651 and a twelve month high of £157.32. The company has a 50-day moving average price of £146.60 and a two-hundred day moving average price of £137.07.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.